2 hepatitis C medications on the way
By The Associated Press
Published: Tuesday, Oct. 22, 2013, 5:51 p.m.
WASHINGTON — Doctors may soon have two new drug options for patients with hepatitis C, just as the liver-destroying virus becomes a major public health concern for millions of baby boomers.
The Food and Drug Administration will hold a public meeting this week to review two experimental medications from Johnson & Johnson and Gilead Sciences. The drugs, if approved, could offer a quicker, more effective approach to eliminating hepatitis C, a blood-borne disease blamed for 15,000 deaths in America this year.
In a review posted online on Tuesday, the FDA reported that J&J's drug Simeprevir has a slightly higher cure rate than available treatments, though it caused rashes and sunburn in some patients.
On Thursday, the FDA will ask a panel of outside experts whether the drug should carry warnings about rashes and sunburn. The agency is not required to follow the panel's advice, though it often does.
The meeting will occur at a time when federal health officials are urging baby boomers to get tested for the virus, which can go unnoticed for decades before causing symptoms.
Between 3 million and 4 million Americans are infected with hepatitis C, and people born between 1945 and 1965 are five times more likely to have it than people of other age groups, the Centers for Disease Control and Prevention reports.
Many baby boomers contracted the virus by sharing needles or having sex with an infected person in their youth. The disease was spread by blood transfusions before 1992, when blood banks began testing for the virus.
“If something is not done soon, all these people who were infected in the '60s and '70s are going to start experiencing the long-term consequences of liver disease,” said Gaston Picchio, head of hepatitis drug development for J&J's Janssen Therapeutics unit.
Most people with hepatitis C do not know they have the virus until after liver damage has occurred, causing abdominal pain, fatigue, itching and dark urine.
For most of the last 20 years, the standard treatment involved a grueling one-year regimen of pills and injections that caused flu-like symptoms and cured fewer than half of patients. Many patients failed to complete the full treatment cycle. Others delayed starting treatment at all in the hopes that more effective treatments would come along.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- California man named as bitcoin creator denies involvement
- Gillibrand sex assault bill halted by fellow Democrat
- Maryland bill would link criminal, gun owners data
- Sex-crimes prosecutor accused in groping
- Shuster plans oversight for DUI program
- Health marketplace targets not signing up, survey shows
- Volunteers reconstruct World War II bomber plane
- Traffic cameras rejected in Ohio ruling
- El Nino could bring relief to U.S.
- Mummified remains found in foreclosed home
- Crisis stymies Obama getaway